This HTML5 document contains 87 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00025/identifier/drugbank/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00025/identifier/national-drug-code-directory/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/patent/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00025/identifier/genbank/
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00025/identifier/uniprotkb/
n5http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00025/identifier/wikipedia/
n4http://www.rxlist.com/cgi/generic2/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00025/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00025
rdf:type
n5:Drug
n5:description
Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
n5:dosage
n11:271B402F-363D-11E5-9242-09173F13E4C5 n11:271B4030-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Titheradge MA, Coore HG: Initial rates of pyruvate transport in mitochondria determined by an "inhibitor-stop" technique. Biochem J. 1975 Sep;150(3):553-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2157
n5:group
investigational approved
n5:halfLife
8.4-19.3 hrs
n5:indication
For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
owl:sameAs
n17:DB00025 n25:DB00025
dcterms:title
Antihemophilic Factor
adms:identifier
n15:Antihemophilic_Factor n18:PA164750168 n22:P00451 n23:M14113 n24:0026-3782-20 n26:DB00025
n5:mechanismOfAction
Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).
n5:packager
n10:271B4001-363D-11E5-9242-09173F13E4C5 n10:271B4002-363D-11E5-9242-09173F13E4C5 n10:271B3FFF-363D-11E5-9242-09173F13E4C5 n10:271B4000-363D-11E5-9242-09173F13E4C5 n10:271B4003-363D-11E5-9242-09173F13E4C5 n10:271B3FFD-363D-11E5-9242-09173F13E4C5 n10:271B3FFE-363D-11E5-9242-09173F13E4C5 n10:271B3FFB-363D-11E5-9242-09173F13E4C5 n10:271B3FFC-363D-11E5-9242-09173F13E4C5
n5:patent
n9:1339477 n9:2124690
n5:synonym
Factor VIII AHF
n19:hasAHFSCode
n20:20-28-16
n5:synthesisReference
James W. Bloom, "Warm ethanol method for preparation of low fibrinogen antihemophilic factor." U.S. Patent US4478825, issued June, 1955.
n12:hasConcept
n13:M0209555
foaf:page
n4:hemofilm.htm n21:antihemophilic-factor-human.html
n5:Molecular-Formula
n7:271B4034-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B4033-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:category
n5:clearance
* 4.1 mL/h•kg [Previously treated pediatric patients]
n5:containedIn
n6:271B401A-363D-11E5-9242-09173F13E4C5 n6:271B401B-363D-11E5-9242-09173F13E4C5 n6:271B4018-363D-11E5-9242-09173F13E4C5 n6:271B4019-363D-11E5-9242-09173F13E4C5 n6:271B4006-363D-11E5-9242-09173F13E4C5 n6:271B4007-363D-11E5-9242-09173F13E4C5 n6:271B4004-363D-11E5-9242-09173F13E4C5 n6:271B4005-363D-11E5-9242-09173F13E4C5 n6:271B4025-363D-11E5-9242-09173F13E4C5 n6:271B4026-363D-11E5-9242-09173F13E4C5 n6:271B4023-363D-11E5-9242-09173F13E4C5 n6:271B4024-363D-11E5-9242-09173F13E4C5 n6:271B4029-363D-11E5-9242-09173F13E4C5 n6:271B402A-363D-11E5-9242-09173F13E4C5 n6:271B4027-363D-11E5-9242-09173F13E4C5 n6:271B4028-363D-11E5-9242-09173F13E4C5 n6:271B401D-363D-11E5-9242-09173F13E4C5 n6:271B401E-363D-11E5-9242-09173F13E4C5 n6:271B401C-363D-11E5-9242-09173F13E4C5 n6:271B4021-363D-11E5-9242-09173F13E4C5 n6:271B4022-363D-11E5-9242-09173F13E4C5 n6:271B401F-363D-11E5-9242-09173F13E4C5 n6:271B4020-363D-11E5-9242-09173F13E4C5 n6:271B402D-363D-11E5-9242-09173F13E4C5 n6:271B402E-363D-11E5-9242-09173F13E4C5 n6:271B4012-363D-11E5-9242-09173F13E4C5 n6:271B402B-363D-11E5-9242-09173F13E4C5 n6:271B4013-363D-11E5-9242-09173F13E4C5 n6:271B402C-363D-11E5-9242-09173F13E4C5 n6:271B4010-363D-11E5-9242-09173F13E4C5 n6:271B4011-363D-11E5-9242-09173F13E4C5 n6:271B4016-363D-11E5-9242-09173F13E4C5 n6:271B4017-363D-11E5-9242-09173F13E4C5 n6:271B4014-363D-11E5-9242-09173F13E4C5 n6:271B4015-363D-11E5-9242-09173F13E4C5 n6:271B400A-363D-11E5-9242-09173F13E4C5 n6:271B400B-363D-11E5-9242-09173F13E4C5 n6:271B4008-363D-11E5-9242-09173F13E4C5 n6:271B4009-363D-11E5-9242-09173F13E4C5 n6:271B400E-363D-11E5-9242-09173F13E4C5 n6:271B400F-363D-11E5-9242-09173F13E4C5 n6:271B400C-363D-11E5-9242-09173F13E4C5 n6:271B400D-363D-11E5-9242-09173F13E4C5
n5:Hydrophobicity
n7:271B4031-363D-11E5-9242-09173F13E4C5
n5:Isoelectric-Point
n7:271B4032-363D-11E5-9242-09173F13E4C5